Opioid Overdose Drug Pipeline Research Report 2024: Current Treatment Patterns, Therapeutic Assessment, Development Activities
15 avr. 2024 09h59 HE
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Opioid Overdose - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.Opioid Overdose Pipeline Insight, 2024...
BioCorRx Reports Business Update for 2023
02 avr. 2024 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
Global Alexipharmic Drugs Market by Application, by Route of Administration, by End-Users, and By Region
12 mars 2024 13h46 HE
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Alexipharmic Drugs Market by Application, by Route of Administration, by End-Users, and By Region" report has been added to ...
Global Substance Abuse Disorder Treatment Research Analysis Report 2024: Public and Private Entities Join Forces to Tackle Substance Abuse Epidemic - Forecasts to 2034
31 janv. 2024 09h44 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Disorder Treatment Market Analysis & Forecast 2024-2034: Market By Treatment; By End-user; and By Region" report has been...
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 07h30 HE
|
DMK Pharmaceuticals Corporation
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI®...
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
13 nov. 2023 10h52 HE
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
22 juin 2023 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis...
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
25 mai 2023 16h26 HE
|
Adamis Pharmaceuticals Corporation
DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical...
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h47 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in...
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
08 mai 2023 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...